Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) and Agenus (NASDAQ:AGEN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.
Analyst Recommendations
This is a summary of recent ratings and price targets for Tectonic Therapeutic and Agenus, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tectonic Therapeutic | 0 | 0 | 6 | 1 | 3.14 |
| Agenus | 0 | 5 | 1 | 0 | 2.17 |
Tectonic Therapeutic currently has a consensus price target of $72.40, indicating a potential upside of 282.66%. Agenus has a consensus price target of $8.75, indicating a potential upside of 194.12%. Given Tectonic Therapeutic’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Tectonic Therapeutic is more favorable than Agenus.
Risk & Volatility
Valuation and Earnings
This table compares Tectonic Therapeutic and Agenus”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tectonic Therapeutic | N/A | N/A | $12.16 million | ($6.53) | -2.90 |
| Agenus | $103.46 million | 0.61 | -$245.76 million | ($10.68) | -0.28 |
Tectonic Therapeutic has higher earnings, but lower revenue than Agenus. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 9.2% of Tectonic Therapeutic shares are held by company insiders. Comparatively, 4.6% of Agenus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Tectonic Therapeutic and Agenus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tectonic Therapeutic | N/A | -35.53% | -31.97% |
| Agenus | -145.89% | N/A | -85.68% |
Summary
Tectonic Therapeutic beats Agenus on 11 of the 14 factors compared between the two stocks.
About Tectonic Therapeutic
Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
About Agenus
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.
